LEUKEMIA

Feature

A New Genomic Dataset May be a Significant Step Forward in Combating Acute Myeloid Leukemia

A dataset comprising 672 tumor specimens collected from 562 patients describes both genetic and functional information about the biology of AML.

Latest News

Participation in Clinical Studies May Be Linked to Higher Remission Rates

By

Complete remission rates were higher for newly diagnosed patients on study compared with newly diagnosed patients off study.

Inotuzumab Ozogamicin May Be Efficacious and Safe in Relapsed Pediatric Acute Lymphoblastic Leukemia

By

The efficacy of inotuzumab ozogamicin in pediatric patients is less understood than in adult patients.

Relapse in Acute Myeloid Leukemia and Dysregulation of Immune Genetic Pathways

By

One of the effects of immune pathway dysregulation was decreased antigen presentation by MHC Class II genes.

The Price Is Right for CAR-T in Pediatric Patients, Analysis Concludes

By Christina Bennett, MS

For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

By Christina Bennett, MS

For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.

Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

By Randi Hernandez

Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

By James Nam, PharmD

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.

Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody

By Randi Hernandez

Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.

Individualized Lenalidomide Plus Chlorambucil and Rituximab May Be Feasible in Advanced CLL

By James Nam, PharmD

The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.

Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials

By James Nam, PharmD

The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

By James Nam, PharmD

Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

By James Nam, PharmD

Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.

Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia

By James Nam, PharmD

Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.

Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards

By James Nam, PharmD

No direct comparison between ibrutinib and chemoimmunotherapy as a first-line treatment exists.

In Search of the Right Sequence for Venetoclax in CLL

By Randi Hernandez

Researchers reveal the results of the phase 2 CLL2-BAG trial, which evaluated sequential bendamustine followed by obinutuzumab and venetoclax in patients with CLL.

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

By James Nam, PharmD

A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

By James Nam, PharmD

A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.

Time of Response to TKI Therapies May Influence Patient Outcomes in CML

By Randi Hernandez

Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

By James Nam, PharmD

There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.

FDA Assigns a Breakthrough Therapy Designation to Quizartinib for Relapsed/Refractory FLT3-ITD AML

By James Nam, PharmD

Quizartinib — an investigational FLT3 inhibitor — is the first agent in its class to demonstrate improved overall survival.

SIGN UP FOR FREE E-NEWSLETTERS